Company
Bold, global biopharmaceutical company headquartered in Dublin, Ireland
Dublin, OS
Every published round Allergan plc took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Allergan plc has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Allergan plc, as distinct from the investments it has made.
Companies Allergan plc has backed that another company then bought. An exit for the holding, not a deal Allergan plc did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Allergan plc is recorded as having been acquired. | ||||
Companies Allergan plc acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Elastagen Pty Ltd | Acquisition | 7 Feb 2018 | US$95m (A$122m) | GBS Ventures (28 Sep 2018), GBS Ventures (7 Feb 2018) |
Stories naming Allergan plc. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The NSW government has engaged Cicada Innovations, via a $7.8m grant, to operate a Westmead incubator supporting early-stage medical technology ventures; the story also recalls Allergan's $350m buyout of Elastagen.
Sydney-based tropoelastin biotech Elastagen agreed to an Allergan takeover offering US$95 million upfront plus contingent payments; the GBS Ventures-backed company previously drew MDF and federal grant funding.
Also GBS Ventures